There was a significant difference observed in pain scores between pediatric patients receiving pegfilgrastim versus those receiving filgrastim after allogenic hematopoietic stem cell transplantation.
Allogenic hematopoietic stem cell transplantation (allo-HSCT), used to treat hematologic malignancies, some metabolic diseases, and immunologic deficiency, can be aided by treatment with granulocyte-colony stimulating factor (G-CSF) therapies. G-CSFs—including filgrastim and the longer-acting pegfilgrastim—can promote hematopoiesis, accelerate immune reconstruction, and reduce the duration of febrile neutropenia.
A recent retrospective analysis compared experience with Chinese-licensed biosimilar pegfilgrastim (manufactured by Qilu Pharmaceutical) and biosimilar filgrastim (manufactured by Kyowa Hakko Kirin) products in treating pediatric patients.
The patients (n = 86), all of whom received allo-HSCT at a single center between 2014 and 2017, had thalassemia major, aplastic anemia, leukemia, and mucopolysaccharidosis. In total, 53 of the patients were treated with pegfilgrastim, and 33 were treated with filgrastim; in both groups, G-CSF was administered 5 days after allo-HSCT. Patients were followed for at least 3 months.
Read more about biosimilar G-CSF agents and stem cell transplantation.
There was no significant difference observed between the patients receiving pegfilgrastim and those receiving filgrastim in terms of time to neutrophil recovery, time to platelet recovery, white blood cell count, or neutrophil percentage. There were also no significant differences between the 2 groups in the incidence of fever for unknown reasons or transplantation-related complications.
However, there was a significant difference observed in pain scores between the 2 groups using the visual analogue scale (and the modified Flacc scale for infants); the pain score was 3.06 (standard deviation [SD], 0.41) for the pegfilgrastim group and 25.18 (SD, 6.22) for the filgrastim group (P <.001). The authors suggest that the patients who received a single dose of pegfilgrastim—versus an average of 9.78 (SD, 2.36) doses of filgrastim—had a less injection-related pain and therefore a lower psychological burden associated with G-CSF treatment.
Additionally, total hospitalization costs were higher for the filgrastim group than for the pegfilgrastim group, though the difference was not statistically significant. The authors indicate that increased pain and higher psychological burden in the filgrastim group may have led to lower compliance with G-CSF treatment.
While the authors note that the long-term effects of using pegfilgrastim versus filgrastim after allo-HSCT need to be investigated, and that larger, multi-center, randomized controlled trials will be needed, their research has “encouraging findings” that support the use of pegfilgrastim in this setting.
Reference
Ye Q, Jiang H, Jiang H. A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation. Ital J Pediatr. 2018;44(1): 63. doi: 10.1186/s13052-018-0482-0.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.